As the world battles COVID-19, practical investments are urgently needed to ensure that decision-makers consult the best and most relevant evidence on COVID-19 before making a decision.
CGD Policy Blogs
COVID-19 Surfaces New Directions for Old Challenges: Three Lasting Ways to Improve Global Health Procurement
Effective and efficient procurement of health products—medicines, diagnostics, and devices—is a critical function of all strong health systems. The pandemic has exacerbated long-standing challenges—as highlighted by a recent CGD Working Group—in the purchasing of both COVID-related emergency supplies and other essential health products.
In a context where global cooperation is needed perhaps more than ever before, how concerned should we be by efforts to “stockpile” potential treatments, and how can we encourage further cooperation? We look at the case of dexamethasone and remdesivir.
As vaccines complete the different phases of development (pre-clinical, phase I, phase II, phase III, regulatory review, and license), results will be published in the scientific literature and announced to the public through the media and press releases. We our currently working as part of a larger group to interview experts and give better guidance on the timelines and probabilities of success for a vaccine against COVID-19. In the meantime, it is important not to read too much into early stage results—this is why.
The authors look at the feasibility of the drug dexamethasone in low-income countries.
Following precedents applied first in wealthy states, more than 140 countries have applied some form of lockdown restrictions to slow their COVID-19 epidemics, but can control measures be made sustainable in low-income countries?
Last month, CGD and the Global Fund to Fight AIDS, Tuberculosis, and Malaria convened a high-level discussion, chaired by CGD President Masood Ahmed, to explore some of the rapidly evolving answers to these questions.
With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.
Using our net health impact calculator and the limited publicly available data to guide the analysis, we find that Ethiopia likely faces significant excess non-COVID-19 deaths in the coming months—possibly more than the COVID-19 deaths avoided by the government’s robust response to the pandemic.
This blog outlines some of the challenges in the global supply of medicines and introduces a methodology that will enable countries to spot early challenges in supply.